Page 95 - Amgen News Today

Saxon Interests Inc. bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the 4th quarter, Holdings Channel.com reports. The fund bought 1,652 shares of the medical research company’s stock, valued at approximately $476,000. Several other institutional investors and hedge funds also recently added to or reduced their stakes in AMGN. […]

Only 25% of weight loss by participants in a clinical trial of Altimmune’s Pemvidutide came from a loss of lean mass

Even if patients with EGFR-mutated lung cancer progress on amivantamab plus chemotherapy, there is a survival benefit over chemotherapy alone, follow-up analyses of PAPILLON and MARIPOSA-2 showed.

VANCOUVER, British Columbia, March 28, 2024 -- Zymeworks Inc. , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the...

S.A. Mason LLC decreased its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 0.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,407 shares of the medical research company’s stock after selling 59 shares during the quarter. Amgen accounts for approximately 1.2% […]

First National Corp MA ADV raised its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 9.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,420 shares of the medical research company’s stock after acquiring an additional 210 shares during […]

First National Corp MA ADV raised its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 9.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,420 shares of the medical research company’s stock after purchasing an […]

Raymond James resumes coverage of Amgen highlighting its diversified portfolio and strong presence across therapeutic areas for sustainable long-term growth. Innovative pipeline in oncology, rare diseases, and obesity offers promise, though uncertainties remain."

Altfest L J & Co. Inc. lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 3.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,816 shares of the medical research company’s stock after selling 117 shares during […]